Literature DB >> 2735330

Acid-secretory response and parietal cell sensitivity in patients with duodenal ulcer before and after treatment with sucralfate or ranitidine.

I N Marks1, G O Young, N A Tigler-Wybrandi, S Bridger, K A Newton.   

Abstract

Patients with endoscopically proved duodenal ulcer were randomly assigned to treatment with either ranitidine 300 mg at bedtime or sucralfate 2 g twice daily for six weeks. Acid-secretory studies were performed before commencement and 60 to 84 hours after cessation of treatment and endoscopic healing was confirmed. Patients were randomly assigned to receive a constant infusion of secretory stimulant: either pentagastrin 0.1 and 6.0 micrograms/kg/hour or histamine acid phosphate 4.0 and 40 micrograms/kg/hour. Acid output in mmol/hour was measured for basal, low dose, and high dose output. Parietal cell sensitivity (PCS) was calculated as the ratio of low-dose acid output: high-dose acid output and expressed as a percentage. Values before and after treatment were compared and significance of differences was determined using the Student paired t test. There was an apparent decrease in basal acid output, low-dose acid output, high-dose acid output, and PCS with ulcer healing, regardless of treatment or stimulant used. Basal acid output, low-dose acid output, high-dose acid output, and PCS were significantly lower in the sucralfate-treated group, but only high-dose acid output decreased significantly in the ranitidine-treated group. These differences may be relevant to early duodenal ulcer relapse in ranitidine-treated patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2735330     DOI: 10.1016/0002-9343(89)90177-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Helicobacter pylori eradication, duodenal ulcer healing, and gastric secretory state.

Authors:  J A Louw; I N Marks
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

Review 2.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

3.  Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.

Authors:  A F Kummer; D A Johnston; I N Marks; G O Young; N A Tigler-Wybrandi; S A Bridger
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

Review 4.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 5.  The H2-receptor antagonist era in duodenal ulcer disease.

Authors:  I N Marks
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.